Detalles de la búsqueda
1.
Predictors for severe persisting pain in rheumatoid arthritis are associated with pain origin and appraisal of pain.
Ann Rheum Dis
; 2024 May 30.
Artículo
en Inglés
| MEDLINE | ID: mdl-38816064
2.
Differential properties of Janus kinase inhibitors in the treatment of immune-mediated inflammatory diseases.
Rheumatology (Oxford)
; 63(2): 298-308, 2024 Feb 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-37624925
3.
Patterns and determinants of response to novel therapies in juvenile and adult-onset polyarthritis.
Rheumatology (Oxford)
; 63(3): 594-607, 2024 Mar 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-37725352
4.
Efficacy Of Baricitinib in Patients With Moderate-To-Severe Rheumatoid Arthritis Up to 6.5 Years Of Treatment: Results Of A Long-Term Study.
Rheumatology (Oxford)
; 2024 Jan 22.
Artículo
en Inglés
| MEDLINE | ID: mdl-38258434
5.
Approaches to optimising access to NICE-approved biologic anti-TNFs for patients with rheumatoid arthritis with moderately active disease.
BMC Med
; 21(1): 55, 2023 02 14.
Artículo
en Inglés
| MEDLINE | ID: mdl-36782189
6.
Anti-GM-CSF otilimab versus tofacitinib or placebo in patients with active rheumatoid arthritis and an inadequate response to conventional or biologic DMARDs: two phase 3 randomised trials (contRAst 1 and contRAst 2).
Ann Rheum Dis
; 82(12): 1516-1526, 2023 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-37699654
7.
Anti-GM-CSF otilimab versus sarilumab or placebo in patients with rheumatoid arthritis and inadequate response to targeted therapies: a phase III randomised trial (contRAst 3).
Ann Rheum Dis
; 82(12): 1527-1537, 2023 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-37696589
8.
Impact of initial therapy with upadacitinib or adalimumab on achievement of 48-week treatment goals in patients with rheumatoid arthritis: post hoc analysis of SELECT-COMPARE.
Rheumatology (Oxford)
; 62(5): 1804-1813, 2023 05 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-36018230
9.
Predicting successful biologics tapering in patients with inflammatory arthritis: Secondary analyses based on the BIOlogical Dose OPTimisation (BIODOPT) trial.
Br J Clin Pharmacol
; 89(10): 3152-3164, 2023 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-37271939
10.
Rituximab versus tocilizumab in anti-TNF inadequate responder patients with rheumatoid arthritis (R4RA): 16-week outcomes of a stratified, biopsy-driven, multicentre, open-label, phase 4 randomised controlled trial.
Lancet
; 397(10271): 305-317, 2021 01 23.
Artículo
en Inglés
| MEDLINE | ID: mdl-33485455
11.
Safety of baricitinib for the treatment of rheumatoid arthritis over a median of 4.6 and up to 9.3 years of treatment: final results from long-term extension study and integrated database.
Ann Rheum Dis
; 81(3): 335-343, 2022 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-34706874
12.
Disease status in human and experimental arthritis, and response to TNF blockade, is associated with MHC class II invariant chain (CD74) isoform expression.
J Autoimmun
; 128: 102810, 2022 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-35245865
13.
Risk of flare after tapering or withdrawal of biologic/targeted synthetic disease-modifying anti-rheumatic drugs in patients with rheumatoid arthritis or axial spondyloarthritis: a systematic review and meta-analysis.
Rheumatology (Oxford)
; 61(8): 3107-3122, 2022 08 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-34864896
14.
The JAK inhibitor baricitinib inhibits oncostatin M induction of proinflammatory mediators in ex-vivo synovial derived cells.
Clin Exp Rheumatol
; 40(9): 1620-1628, 2022 Sep.
Artículo
en Inglés
| MEDLINE | ID: mdl-34665696
15.
A vanA vancomycin-resistant Enterococcus faecium ST80 outbreak resulting from a single importation event.
J Antimicrob Chemother
; 77(1): 31-37, 2021 12 24.
Artículo
en Inglés
| MEDLINE | ID: mdl-34718605
16.
TLR expression profiles are a function of disease status in rheumatoid arthritis and experimental arthritis.
J Autoimmun
; 118: 102597, 2021 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-33493980
17.
Targeted literature review of current treatments and unmet need in moderate rheumatoid arthritis in the United Kingdom.
Rheumatology (Oxford)
; 60(11): 4972-4981, 2021 11 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-34080612
18.
Efficacy of baricitinib in patients with moderate-to-severe rheumatoid arthritis with 3 years of treatment: results from a long-term study.
Rheumatology (Oxford)
; 60(5): 2256-2266, 2021 05 14.
Artículo
en Inglés
| MEDLINE | ID: mdl-33200220
19.
Patient-reported outcome measures in systemic lupus erythematosus by a web-based application: A randomized, crossover, agreement study.
Lupus
; 30(13): 2124-2134, 2021 Nov.
Artículo
en Inglés
| MEDLINE | ID: mdl-34719299
20.
Baricitinib versus Placebo or Adalimumab in Rheumatoid Arthritis.
N Engl J Med
; 376(7): 652-662, 2017 02 16.
Artículo
en Inglés
| MEDLINE | ID: mdl-28199814